Search results for "Interleukins"

showing 7 items of 137 documents

Influence of cold ischemia time on complement activation, neopterin, and cytokine release in liver transplantation.

2004

The aim of this study was to determine whether a cold ischemia time (CIT) of12 hours influences the activation of complement as well as the plasma concentrations of neopterin, interleukin (IL)-6, or IL-8 in orthotopic liver transplantation (OLT).Eighteen consecutive patients undergoing OLT using a veno-venous bypass technique were divided into 2 groups: duration of CIT12 hours (group 1; n = 11), and CIT12 hours (group 2; n = 7). Blood samples were drawn preoperatively, 1 minute before, and 120 minutes after reperfusion.Preoperatively, complement split products, neopterin, IL-6, and IL-8 levels did not differ between the groups. At 120 minutes after reperfusion, the concentrations of C3a, SC…

medicine.medical_specialtyTime Factorsmedicine.medical_treatmentIschemiaLiver transplantationGastroenterologyCold Ischemia TimeNeopterinchemistry.chemical_compoundIschemiaInternal medicinemedicineHumansComplement ActivationTransplantationbusiness.industryInterleukinsNeopterinInterleukinOrgan PreservationHypothermiamedicine.diseaseComplement systemLiver TransplantationTransplantationCold Temperaturesurgical procedures operativechemistryLiverImmunologyCytokinesSurgerymedicine.symptombusinessTransplantation proceedings
researchProduct

Interleukin-32 in systemic sclerosis, a potential new biomarker for pulmonary arterial hypertension

2020

Abstract Background Pulmonary arterial hypertension (PAH) is a severe complication of systemic sclerosis (SSc), associated with a progressive elevation in pulmonary vascular resistance and subsequent right heart failure and death. Due to unspecific symptoms, the diagnosis of PAH is often delayed. On this basis, it is of great value to improve current diagnostic methods and develop new strategies for evaluating patients with suspected PAH. Interleukin-32 (IL-32) is a proinflammatory cytokine expressed in damaged vascular cells, and the present study aimed to assess if this cytokine could be a new biomarker of PAH during SSc. Methods The IL-32 expression was evaluated in the sera and skin sam…

medicine.medical_specialtylcsh:Diseases of the musculoskeletal systemHypertension Pulmonarymedicine.medical_treatment030204 cardiovascular system & hematologyPulmonary arterial hypertensionGastroenterologyProinflammatory cytokineSystemic sclerosi03 medical and health sciences0302 clinical medicineInternal medicinemedicine.arterysystemic sclerosis; pulmonary arterial hypertension; IL-32medicineHumansskin and connective tissue diseases030203 arthritis & rheumatologyScleroderma Systemicintegumentary systembusiness.industryInterleukinsRheumatologyInterleukin 32Cytokinemedicine.anatomical_structureIL-32; Pulmonary arterial hypertension; Systemic sclerosisIL-32Pulmonary arteryVascular resistanceSystemic sclerosisBiomarker (medicine)Immunohistochemistrylcsh:RC925-935businessBiomarkersResearch ArticleArthritis Research & Therapy
researchProduct

Are biological drugs effective and safe in older severe asthmatics?

2019

Introduction: The treatment of asthma in older ages follows the recommendations of international guidelines for the management of asthma in younger ages, although older age has always represented an exclusion criterion for eligibility to pharmacological trials. This poses a clinical challenge when deciding whether elderly severe asthmatics are candidates for biological drugs. Areas covered: The current article has a narrative structure to review the current literature on efficacy and safety of novel pharmacological drugs against immunoglobulins and interleukins that mediate and orchestrate the main inflammatory pathways in severe asthma, in order to explore whether older subjects (i.e. >…

medicine.medical_specialtypulmonary eosinophilia/drug therapyeducationImmunoglobulinsmonoclonal030204 cardiovascular system & hematologySettore MED/10 - Malattie Dell'Apparato RespiratorioAnti-asthmatic AgentSeverity of Illness IndexBiological drugs03 medical and health sciences0302 clinical medicineimmune system diseasesInternal medicineSeverity of illnessImmunoglobulinHumansMedicineAnti-Asthmatic AgentPharmacology (medical)Age FactorAnti-Asthmatic AgentsAsthmaAgedRandomized Controlled Trials as TopicBiological ProductsAsthma/drug therapybiologyhumanizedbusiness.industryInterleukinsAge FactorsGeneral MedicineInterleukinmedicine.diseaseAsthmarespiratory tract diseasesantibodie030220 oncology & carcinogenesisMonoclonalPractice Guidelines as Topicbiology.proteinBiological Productanti-asthmatic agents/pharmacologyAntibodybusinessHuman
researchProduct

IL-27 controls the development of inducible regulatory T cells and Th17 cells via differential effects on STAT1

2007

IL-27 is an IL-12-related cytokine frequently present at sites of inflammation that can promote both anti- and pro-inflammatory immune responses. Here, we have analyzed the mechanisms how IL-27 may drive such divergent immune responses. While IL-27 suppressed the development of proinflammatory Th17 cells, a novel role for this cytokine in inhibiting the development of anti-inflammatory, inducible regulatory T cells (iTreg) was identified. In fact, IL-27 suppressed the development of adaptive, TGF-beta-induced Forkhead box transcription factor p3-positive (Foxp3(+)) Treg. Whereas the blockade of Th17 development was dependent on the transcription factor STAT1, the suppression of iTreg develo…

medicine.medical_treatmentImmunologyMice Transgenicchemical and pharmacologic phenomenaInflammationBiologyT-Lymphocytes RegulatoryProinflammatory cytokineMiceImmune systemT-Lymphocyte SubsetsmedicineAnimalsImmunology and AllergySTAT1IL-2 receptorTranscription factorInterleukinsFOXP3Forkhead Transcription FactorsFlow CytometryCoculture TechniquesCell biologySTAT1 Transcription FactorCytokineImmunologybiology.proteinmedicine.symptomEuropean Journal of Immunology
researchProduct

Major histocompatibility complex regulation of cytokine production.

1996

This review describes the phenomenon of the major histocompatibility complex (MHC) control of cytokine production both in experimental animals and in humans. H-2 (mouse MHC) regulates which type of cytokine is selectively produced in response to the hapten trinitrophenyl (TNP). T cells from TNP-immune H-2k mice produce interferon-gamma (IFN-gamma), interleukin-2 (IL-2), IL-3, IL-5, tumor necrosis factor-alpha (TNF-alpha), IL-10, and very low levels of IL-4 on reexposure to the specific antigen in vitro. By contrast, T cells from H-2d mice produce IL-3, TNF-alpha, IL-10, and IL-4 but very low levels of IL-2, IL-5 and IFN-gamma. As MHC-congenic matched strains (BALB/k and BALB/c) are used, th…

medicine.medical_treatmentImmunologychemical and pharmacologic phenomenaMajor histocompatibility complexPeripheral blood mononuclear cellMajor Histocompatibility ComplexInterferon-gammaMiceImmune systemAntigenVirologyImmunopathologymedicineAnimalsHumansbiologyTumor Necrosis Factor-alphaInterleukinsH-2 AntigensCell BiologyCytokineImmunologyAntibody Formationbiology.proteinCytokinesTumor necrosis factor alphaHapten
researchProduct

Mast cell growth-enhancing activity (MEA) is structurally related and functionally identical to the novel mouse T cell growth factor P40/TCGFIII (int…

1990

We have previously shown that certain bone marrow-derived mast cell (BMMC) lines proliferate in response to a mast cell growth-enhancing activity (MEA) that is distinct from interleukin (IL) 3 and IL 4. Here we provide evidence that MEA is identical with the recently cloned mouse T cell growth factor P40. The evidence is as follows: (a) recombinant P40 displayed all the biological activities ascribed to MEA: it supported the growth of MEA-sensitive BMMC lines, it induced IL 6 secretion by these cells, and it enhanced survival of primary mast cell cultures; (b) highly purified MEA stimulated the growth of P40-dependent cell lines; (c) a rabbit monospecific antiserum directed against P40 spec…

medicine.medical_treatmentT-LymphocytesImmunologyBone Marrow CellsBiologyIn Vitro TechniquesBinding CompetitiveMicemedicineImmunology and AllergyAnimalsInterleukin 9Mast CellsGrowth SubstancesInterleukin 4Cell growthGrowth factorImmune SeraInterleukinsInterleukin-9Interleukinfood and beveragesMast cellCell biologyCytokinemedicine.anatomical_structureCell cultureImmunologyEuropean journal of immunology
researchProduct

The role of innate and lymphoid IL-22-producing cells in the immunopathology of primary Sjögren's syndrome

2014

In primary Sjögren's syndrome (pSS) a complex of interconnections between epithelial barrier, innate and adaptive immunity occurs. IL-22 is a pleiotropic cytokine that in pSS may be placed at the intersection of the adaptive and innate branches of immunity. Some evidence suggests that, in pSS, IL-22 may play a prominent pro-inflammatory role driving the early phase of tissue and systemic inflammation and participating in the self-perpetuation of disease. Despite contradictory data in literature about the role of NK cells in pSS, recent data also suggest an important contribution of this subset of cells of the innate immune system in the development and perpetuation of inflammation. Here, we…

musculoskeletal diseasesImmunologyInflammationAdaptive ImmunitySystemic inflammationInterleukin 22stomatognathic systemImmunityImmunopathologymedicineHumansImmunology and AllergyInnateKiller CellInnate immune systembusiness.industryInterleukinsInnate lymphoid cellImmunityInterleukinAcquired immune systemeye diseasesImmunity InnateKiller Cells Naturalstomatognathic diseasesSjogren's SyndromeImmunologyNaturalmedicine.symptombusinessHuman
researchProduct